Figure 3.
Adverse events most commonly increased in patients treated with 177Lu-PSMA-617 vs. ARPI change in the phase 3 PSMAfore trial (Δ ≥ 5%) [27]. ARPI, androgen receptor pathway inhibitor; LuPSMA, 177Lu-PSMA-617.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.